163 related articles for article (PubMed ID: 33564472)
1. The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure.
Fan SX; Zeng P; Li ZJ; Wang J; Liang JQ; Liao YR; Hu YX; Xu MT; Wang M
J Ophthalmol; 2021; 2021():9879503. PubMed ID: 33564472
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.
Yu Y; Hu YX; Lu MX; Ouyang ZL; Xu MT; Zhao LY; Wang M
Ophthalmol Ther; 2024 Apr; 13(4):1015-1024. PubMed ID: 38376797
[TBL] [Abstract][Full Text] [Related]
3. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.
Zeng P; Fan SX; Li ZJ; Peng YY; Hu YX; Xu MT; Wang M
J Ophthalmol; 2019; 2019():7602419. PubMed ID: 31011452
[TBL] [Abstract][Full Text] [Related]
6. Intraocular pressure and superior ophthalmic vein blood flow velocity in Graves' orbitopathy: relation with the clinical features.
Konuk O; Onaran Z; Ozhan Oktar S; Yucel C; Unal M
Graefes Arch Clin Exp Ophthalmol; 2009 Nov; 247(11):1555-9. PubMed ID: 19609549
[TBL] [Abstract][Full Text] [Related]
7. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.
Sánchez-Bilbao L; Martínez-López D; Revenga M; López-Vázquez Á; Valls-Pascual E; Atienza-Mateo B; Valls-Espinosa B; Maiz-Alonso O; Blanco A; Torre-Salaberri I; Rodríguez-Méndez V; García-Aparicio Á; Veroz-González R; Jovaní V; Peiteado D; Sánchez-Orgaz M; Tomero E; Toyos-Sáenz de Miera FJ; Pinillos V; Aurrecoechea E; Mora Á; Conesa A; Fernández-Prada M; Troyano JA; Calvo-Río V; Demetrio-Pablo R; González-Mazón Í; Hernández JL; Castañeda S; González-Gay MÁ; Blanco R
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32878150
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with severity of orbitopathy in patients with Graves' disease.
Nabi T; Rafiq N
Taiwan J Ophthalmol; 2020; 10(3):197-202. PubMed ID: 33110751
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients.
Villagelin D; Romaldini J; Andrade J; Santos R; Milkos A; Teixeira PFDS; Ward LS
Front Endocrinol (Lausanne); 2019; 10():192. PubMed ID: 31024443
[No Abstract] [Full Text] [Related]
11. Topical Treatment of Elevated Intraocular Pressure in Patients with Graves' Orbitopathy.
Gumińska M; Goś R; Śmigielski J; Nowak MS
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33322192
[No Abstract] [Full Text] [Related]
12. Intraocular pressure lowering effect of orbital decompression is related to increased venous outflow in Graves orbitopathy.
Onaran Z; Konuk O; Oktar SÖ; Yücel C; Unal M
Curr Eye Res; 2014 Jul; 39(7):666-72. PubMed ID: 24502333
[TBL] [Abstract][Full Text] [Related]
13. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
[TBL] [Abstract][Full Text] [Related]
14. Correlation between Structural and Functional Changes in Patients with Raised Intraocular Pressure Due to Graves' Orbitopathy.
Bagatin F; Prpić A; Škunca Herman J; Zrinšćak O; Iveković R; Vatavuk Z
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535069
[TBL] [Abstract][Full Text] [Related]
15. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
16. [The corneal biomechanical properties of patients with Graves' orbitopathy].
Zhang Y; She XX; Yu XJ; Chen LF; Shen LJ
Zhonghua Yan Ke Za Zhi; 2016 Apr; 52(4):263-7. PubMed ID: 27094063
[TBL] [Abstract][Full Text] [Related]
17. Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.
Barrio-Barrio J; Sabater AL; Bonet-Farriol E; Velázquez-Villoria Á; Galofré JC
J Ophthalmol; 2015; 2015():249125. PubMed ID: 26351570
[TBL] [Abstract][Full Text] [Related]
18. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
Schuh A; Ayvaz G; Baldeschi L; Baretić M; Bechtold D; Boschi A; Brix TH; Burlacu MC; Ciric J; Covelli D; Currò N; Donati S; Eckstein AK; Fichter N; Führer D; Horn M; Jabłońska-Pawlak A; Juri Mandić J; Kahaly GJ; Konuk O; Langbein A; Lanzolla G; Marcocci C; Marinò M; Miśkiewicz P; Beleslin BN; Pérez-Lázaro A; Pérez-López M; Ponto KA; Quinn A; Rudofsky G; Salvi M; Schittkowski MP; Tanda ML; Toruner F; Vaidya B; Hintschich CR
Br J Ophthalmol; 2024 Jan; 108(2):294-300. PubMed ID: 36627174
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of increased intraocular pressure in patients with Graves' ophthalmopathy and association with ophthalmic signs and symptoms in the north-west of Iran.
Eslami F; Borzouei S; Khanlarzadeh E; Seif S
Clin Ophthalmol; 2019; 13():1353-1359. PubMed ID: 31440023
[TBL] [Abstract][Full Text] [Related]
20. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.
Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A
Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
